# US 2016/0250310 A1 · Galectin-3 as immunological target

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250310 A1
- Document ID: US20160250310A1
- Status: Published application
- Kind: A1
- Application number: 15/149,598
- Filed: 2016-05-09
- Published: 2016-09-01
- Earliest claimed: 2008-12-03
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Elizabeth Marion Jaffee; Lanqing Huang; Lei Zheng
- Web page: https://patentgrep.com/patent/US20160250310A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0011: {Cancer antigens}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/303: {Liver or Pancreas}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/575: {humoral response}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 2333/4724: Lectins
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of inhibiting a tumor in a patient comprising
administering to the patient an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell vaccine; and
administering to the patient a monoclonal antibody which specifically binds to galectin-3, thereby inhibiting a tumor in the patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein the tumor is a pancreatic tumor.

### Claim 20 (depends on 18)

The method of claim 18, wherein the tumor is selected from the group consisting of a melanoma, a kidney tumor, a prostate tumor, and a liver tumor.

### Claim 21 (depends on 18)

The method of claim 18, wherein the patient has previously been treated with chemotherapy.

### Claim 22 (depends on 21)

The method of claim 21, wherein the patient has received radiochemotherapy.

### Claim 23 (depends on 18)

The method of claim 18, wherein said antibody is adoptively transfused into the patient.

### Claim 24

A method of inhibiting tumor metastasis comprising
administering to the patient an allogeneic, GM-CSF-secreting tumor cell vaccine; and
administering to the patient a monoclonal antibody which specifically binds to galectin-3, thereby inhibiting tumor metastasis in the patient.

### Claim 25 (depends on 24)

The method of claim 24, wherein the patient has previously been treated with chemotherapy.

### Claim 26 (depends on 25)

The method of claim 25, wherein the patient has received radiochemotherapy.

### Claim 27 (depends on 24)

The method of claim 24, wherein said antibody is adoptively transfused into the patient.

### Claim 28 (depends on 24)

The method of claim 24, wherein the tumor is selected from the group consisting of a melanoma, a kidney tumor, a prostate tumor, and a liver tumor.

### Claim 29 (depends on 24)

The method of claim 24, wherein the tumor is a pancreatic tumor.

### Claim 30 (depends on 24)

The method of claim 24, wherein the patient has had a pancreaticoduodenectomy.

### Claim 31

A method of determining a favorable clinical outcome in a pancreatic ductal adenocarcinoma patient whose tumor has been resected, wherein the patient has received a GM-CSF-secreting pancreatic tumor vaccine comprising:
detecting antibodies to galectin-3 in the serum obtained from the patient, wherein the antibodies are a positive indicator of favorable clinical outcome.

### Claim 32 (depends on 31)

The method of claim 31, wherein the patient has received a vaccine comprising an epitope of galectin-3 protein.
